MEI Pharma Inc. (MEIP)
undefined
undefined%
At close: undefined
2.70
1.89%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.

The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.

MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.

The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.

MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma Inc.
MEI Pharma Inc. logo
Country United States
IPO Date Dec 18, 2003
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Yomara Gomez-Naiden

Contact Details

Address:
11455 El Camino Real
San Diego, California
United States
Website https://www.meipharma.com

Stock Details

Ticker Symbol MEIP
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001262104
CUSIP Number 55279B202
ISIN Number US55279B3015
Employer ID 51-0407811
SIC Code 2834

Key Executives

Name Position
Anne Frese Chief People Officer
David A. Walsey J.D., L.L.M. Senior Vice President of Corporate Affairs
Dr. Robert D. Mass Strategic Advisor
Nicole Chyoko Iida Vice President of Legal Affairs
Yomara Gomez-Naiden Senior Vice President of Operations & Quality

Latest SEC Filings

Date Type Title
Nov 25, 2024 8-K Current Report
Nov 14, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Oct 25, 2024 8-K Current Report
Sep 19, 2024 10-K Annual Report
Sep 19, 2024 8-K Current Report
Aug 02, 2024 8-K Current Report
Jul 30, 2024 8-K Current Report
Jul 22, 2024 8-K Current Report
Jun 25, 2024 8-K Current Report